Doximity (DOCS) Competitors $63.58 -2.36 (-3.57%) Closing price 03:59 PM EasternExtended Trading$63.51 -0.07 (-0.10%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock DOCS vs. VEEV, XYZ, DDOG, EA, ZS, TEAM, SRAD, BIDU, WIT, and TTDShould you be buying Doximity stock or one of its competitors? The main competitors of Doximity include Veeva Systems (VEEV), Block (XYZ), Datadog (DDOG), Electronic Arts (EA), Zscaler (ZS), Atlassian (TEAM), Sportradar Group (SRAD), Baidu (BIDU), Wipro (WIT), and Trade Desk (TTD). These companies are all part of the "computer software" industry. Doximity vs. Its Competitors Veeva Systems Block Datadog Electronic Arts Zscaler Atlassian Sportradar Group Baidu Wipro Trade Desk Doximity (NASDAQ:DOCS) and Veeva Systems (NYSE:VEEV) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Do institutionals & insiders believe in DOCS or VEEV? 87.2% of Doximity shares are owned by institutional investors. Comparatively, 88.2% of Veeva Systems shares are owned by institutional investors. 31.3% of Doximity shares are owned by company insiders. Comparatively, 10.3% of Veeva Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is DOCS or VEEV more profitable? Doximity has a net margin of 36.60% compared to Veeva Systems' net margin of 27.34%. Doximity's return on equity of 21.75% beat Veeva Systems' return on equity.Company Net Margins Return on Equity Return on Assets Doximity36.60% 21.75% 18.64% Veeva Systems 27.34%13.96%11.38% Which has more risk and volatility, DOCS or VEEV? Doximity has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Veeva Systems has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Does the media prefer DOCS or VEEV? In the previous week, Veeva Systems had 8 more articles in the media than Doximity. MarketBeat recorded 28 mentions for Veeva Systems and 20 mentions for Doximity. Veeva Systems' average media sentiment score of 1.47 beat Doximity's score of 1.15 indicating that Veeva Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Doximity 13 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veeva Systems 24 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, DOCS or VEEV? Veeva Systems has higher revenue and earnings than Doximity. Doximity is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDoximity$589.64M20.19$147.58M$1.1754.34Veeva Systems$2.75B16.89$714.14M$4.7260.16 Do analysts rate DOCS or VEEV? Doximity currently has a consensus target price of $66.21, indicating a potential upside of 4.15%. Veeva Systems has a consensus target price of $274.17, indicating a potential downside of 3.45%. Given Doximity's stronger consensus rating and higher probable upside, equities research analysts clearly believe Doximity is more favorable than Veeva Systems.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Doximity 0 Sell rating(s) 10 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.64Veeva Systems 2 Sell rating(s) 8 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryDoximity beats Veeva Systems on 10 of the 17 factors compared between the two stocks. Get Doximity News Delivered to You Automatically Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOCS vs. The Competition Export to ExcelMetricDoximityCustom computer programming services IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.91B$1.90B$5.76B$9.64BDividend YieldN/AN/A3.91%4.09%P/E Ratio63.588.8330.7725.11Price / Sales20.193.89456.03116.28Price / Cash81.3234.9925.2228.45Price / Book11.523.549.385.96Net Income$147.58M$17.22M$3.26B$265.37M7 Day Performance2.83%-0.39%1.90%0.97%1 Month Performance5.84%0.97%3.76%2.49%1 Year Performance76.55%1.02%28.98%20.23% Doximity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOCSDoximity2.9407 of 5 stars$63.58-3.6%$66.21+4.1%+84.4%$11.91B$589.64M63.58890News CoverageVEEVVeeva Systems3.9505 of 5 stars$277.35-1.7%$274.17-1.1%+46.9%$45.32B$2.86B58.767,291Positive NewsXYZBlock3.447 of 5 stars$73.01-0.5%$78.45+7.5%N/A$44.90B$24.12B15.6311,372DDOGDatadog4.748 of 5 stars$128.81-1.6%$151.72+17.8%+12.3%$44.48B$2.68B368.026,500Positive NewsAnalyst ForecastEAElectronic Arts4.4189 of 5 stars$176.11+5.1%$166.35-5.5%+14.0%$44.06B$7.46B44.1414,500Insider TradeZSZscaler3.508 of 5 stars$271.18+0.5%$296.82+9.5%+43.6%$42.22B$2.17B-1,043.007,348TEAMAtlassian4.861 of 5 stars$159.28-5.2%$259.76+63.1%+9.7%$41.81B$5.22B-160.8912,157Positive NewsAnalyst ForecastHigh Trading VolumeSRADSportradar Group2.9662 of 5 stars$28.12+1.8%$29.88+6.2%+182.8%$31.29B$1.19B78.114,582News CoveragePositive NewsBIDUBaidu4.7168 of 5 stars$85.99-1.6%$105.09+22.2%+1.3%$29.70B$134.06B8.5335,900Trending NewsUpcoming EarningsOptions VolumeWITWipro2.2116 of 5 stars$2.66-0.2%N/A-54.6%$27.77B$892.59B17.13233,346TTDTrade Desk3.974 of 5 stars$53.17-2.0%$91.61+72.3%-45.8%$26.13B$2.44B64.063,522Trending NewsAnalyst DowngradeShort Interest ↑High Trading Volume Related Companies and Tools Related Companies VEEV Alternatives XYZ Alternatives DDOG Alternatives EA Alternatives ZS Alternatives TEAM Alternatives SRAD Alternatives BIDU Alternatives WIT Alternatives TTD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOCS) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Doximity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access